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Abstract
The emergence of resistant HIV strains, together with the severe side-effects of existing drugs and lack of development of
effective anti-HIV vaccines highlight the need for novel antivirals, as well as innovative methods to facilitate their discovery.
Here, we have developed an assay in T-cells to monitor the proteolytic activity of the HIV-1 protease (PR). The assay is based
on the inducible expression of HIV-1 PR fused within the Gal4 DNA-binding and transactivation domains. The fusion protein
binds to the Gal4 responsive element and activates the downstream reporter, enhanced green fluorescent protein (eGFP)
gene only in the presence of an effective PR Inhibitor (PI). Thus, in this assay, eGFP acts as a biosensor of PR activity, making
it ideal for flow cytometry based screening. Furthermore, the assay was developed using retroviral technology in T-cells,
thus providing an ideal environment for the screening of potential novel PIs in a cell-type that represents the natural milieu
of HIV infection. Clones with the highest sensitivity, and robust, reliable and reproducible reporter activity, were selected.
The assay is easily adaptable to other PR variants, a multiplex platform, as well as to high-throughput plate reader based
assays and will greatly facilitate the search for novel peptide and chemical compound based PIs in T-cells.
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Introduction
The Human Immunodeficiency Virus (HIV) was identified as
the causative agent of Acquired Immuno Deficiency Syndrome
(AIDS) in 1983 [1] and has since resulted in over 33 million deaths
(UNAIDS/WHO Report 2009). HIV, a lentivirus belonging to the
Retroviridae family of viruses, has a ,9.6kb diploid RNA genome,
encoding nine genes and at least 15 protein products, resulting
from various mechanisms including alternative splicing, ribosomal
frame shifting and proteolytic cleavage of the proteome [2,3].
In spite of the lack of progress in the field of vaccine
development against HIV, three decades of research has resulted
in various antivirals. The antiviral drugs developed so far target
the viral proteins, including Protease (PR), Reverse Transcriptase,
Integrase and Envelope (fusion process), or the cellular receptors
involved in viral entry. In total, about 32 inhibitors (11 targeting
PR) have been approved by the FDA, since the first Protease
Inhibitor (PI), Saquinavir was launched in 1995 [4]. Inhibitors,
supplied as a cocktail of drugs of three or more inhibitors through
Highly Active Anti-Retroviral Therapy (HAART) have resulted in
a drastic reduction in the number of AIDS-related deaths [5].
HIV PR, a 99 amino acid aspartyl protease, is responsible for the
post-translational cleavage of the HIV Gag and Gag-Pol poly-
protein precursor proteins in the host [6,7]. PR targets all the
proteolytic cleavage sites within the viral proteome, except the
envelope gp120/gp41 boundary [8,9], which is cleaved by the host
pro-protein convertase furin or furin like-proteases [10,11]. The
catalytic core of PR consists of the Asp, Thr, Gly triad, and
mutations at Asp25 have been demonstrated to result in the loss of
catalytic activity [12]. PR also has autocatalytic properties, enabling
its own removal from the precursor poly-protein, following
dimerization of the Gag-Pol precursor protein [13]. PR activity is
absolutely necessary for the production of replication-competent
virus, thus making processing by PR an obvious target for anti-
retroviral drug development [14]. One of the earliest identified
inhibitors of PR activity was Pepstatin A, an aspartyl protease
inhibitor, which results in the impaired processing of HIV proteins,
leading to the production of aberrant virions [15,16].
The majority of assays developed so far, in order to screen for
PIs, have been designed in vitro [17–19] in bacterial [20,21], or
yeast cells [22]. The lack of assays for PR activity in mammalian
cells is, in general, due to the cytotoxic effects of PR [23]. The
recently developed mammalian cell-based assays [24,25], although
invaluable, may not provide accurate evaluation of the inhibitory
effects of putative novel drugs on PR as they are not performed in
the natural environment of HIV infection, T-cells. Moreover, most
of the assays are not adaptable for efficient and reliable high-
throughput screening. The growing need for effective assays,
which can aid in drug discovery, prompted us to develop a simple
yet rapid and straightforward method for monitoring PR activity.
The assay, developed in T-cells, will thus facilitate the search for
novel PIs/competitors in a cell type naturally infected by HIV.
The assay described here is based on the classical Gal4-UAS
system, a system broadly utilized for gene expression studies [26].
The yeast Gal4 protein represents a prototypic transcription factor
consisting of two separate domains: an N-terminal DNA-binding
domain (DBD: amino-acids 1–147) and a C-terminal trans-
activation domain (TAD: amino-acids 768–881). The Gal4 protein
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its DBD and activates transcription of downstream genes through
its TAD. However, when the two Gal4 domains are separated,
neither of them can function as a transcription factor by itself [27].
Murray et al., in 1993 first demonstrated the ability of HIV-1 PR
fused within Gal4 domains to autocatalytically remove itself,
leaving behind the two non-functional domains of Gal4 [22].
However, in the presence of PI, or when the PR/Gal4 fusion
protein is mutated at the catalytic site, the fusion protein remains
intact, retaining its ability to bind to UAS and subsequently
activate transcription. This concept has also been applied for the
characterization of the autocatalytic activity, of other proteases like
the 3C protease of coxsackievirus B3 [28]. We exploited this
property of the Gal4 system to express a reporter gene dependent
on PR activity, the expression of the reporter gene being inversely
proportional to the autocatalytic activity of PR, thus serving as the
basis for our assay.
The assay described in this paper is based on the expression of
the PR/Gal4 fusion in an inducible manner via a Tet-On system
(adapted from Clontech), thus drastically reducing the possible
toxic side-effects of PR. The reverse tetracycline transactivator
(rtTA) used in this system allows for the induction of PR/Gal4
expression by the addition of tetracycline (Tet) or doxycycline
(Dox), only when needed. eGFP, the sensor for PR activity, will be
expressed only when PR/Gal4 expression is induced in the
presence of a PI. Most importantly, all the assay elements have
been stably expressed in mammalian cells using retroviral
technology. Finally, we established T-cell lines from clones with
the highest sensitivity showing robust, reliable and reproducible
behavior. This is the first time a cell-based assay for monitoring
PR activity has been developed in T-cells, the natural milieu of
HIV infection, thus providing an efficient way to search for novel
inhibitors/competitors of PR, which could lead to the develop-
ment of new therapeutics against HIV.
Results
A Gal4/PR fusion protein that activates reporter gene
expression only when inhibited
WeestablishedastableT-cellline,whichwillprovidethebasisfor
an assay that facilitates monitoringof HIV-1PR activity,as outlined
inFig.1.Forthis purpose,we firstverified that eachoftheelements
of the assay responded as expected in a transient manner, prior to
proceeding with the establishment of stable cell lines. A reporter
vector, referred to as pFR-eGFP, containing a 5xUAS Gal4
responsive element upstream of a minimal CMV (mCMV)
promoter followed by the eGFP gene (Fig. 2A) was transiently
expressed in adherent HEK293T cells and these cells showed little
to no background (Figs. 2B and 2C). Next, we co-transfected the
reporter vector with pcDNA3.1-Gal4 (Fig. 2A), a construct based
on the mammalian expression vector, pcDNA3.1. The Gal4 gene
utilized here, minimal Gal4, encodes only the DBD and TAD
segments of Gal4. Even though other variants of Gal4, such as
Gal4VP16, are capable of higher levels of induction under the UAS
control, minimal Gal4 allows for insertion of a proteolytic enzyme
within its well-characterized domains, while still retaining high level
of transcriptional activity. As expected, co-transfection of the
reporter vector with pcDNA-Gal4 led to a dramatic induction of
eGFP expression in 293T cells (Figs 2B and 2C).
Next, we corroborated that the insertion of the PR sequence
within Gal4, between DBD and TAD, does not disrupt the
transcriptional activity of Gal4. To test this, we first introduced PR
D25A, an inactive version of PR (PRm), between the Gal4
domains. In addition to the PR sequence, based on the HXB2
HIV-1 genome, 22 upstream and 32 downstream amino acids (to
include the PR cleavage sites) was introduced in between the Gal4
DBD and TAD (Fig. 2A). As PR D25A has been shown to lack
catalytic activity, it should not be able to separate the domains,
and thus disrupt the ability of the DBD and TAD to work in
conjunction to activate eGFP expression. As expected, reporter
and pcDNA-PRm/Gal4 co-transfection in 293T cells resulted in
significant eGFP expression (Figs. 2B and 2C). Although the
induction of eGFP expression by the PRm/Gal4 fusion was lower
than that of Gal4 alone, the level of activation was clear,
corroborating that the insertion of the specific PR sequence ‘per se’
does not have any major impact on Gal4 function.
The PRm sequence was then substituted with the wild-type,
active PR sequence. This sequence contained the exact same
additional 22-upstream and 32-downstream amino acids of PR,
but retained the wild-type aspartic acid residue at position 25.
Importantly, co-transfection of reporter and wild-type PR/Gal4
fusion vectors led to a significant reduction in eGFP expression as
compared to PRm/Gal4 (Figs. 2B and 2C). Finally, it was
crucial to verify that addition of PI would reconstitute the ability of
PR/Gal4 to activate the reporter and thus result in eGFP
expression. For this purpose, HEK293T cells were pre-treated
with 10mM Indinavir (IDV, chosen as an example of FDA-
approved PI) prior to transfection of reporter and PR/Gal4
vectors. While control cells or cells incubated with DMSO alone
lacked eGFP expression, cells incubated with 10mM IDV showed a
drastic induction of eGFP (Figs. 2B and 2C).
Design of lentiviral constructs for the inducible
expression of PR in T-cells
Next, we wanted to test if these results could be reproduced in
T-cells, a cell-type that represents a more natural milieu for HIV-1
infection. For this purpose, we utilized retroviral technology [29]
Figure 1. Assay overview. (A) Wild type Gal4 as control, without
Dox. In the absence of Dox, rtTA can not bind to the Tet-Responsive
Element (TRE) and consequently, there is no eGFP expression from the
reporter construct. In the presence of Dox, rtTA binds to TRE and
induces eGFP expression. (B) The PR/Gal4 fusion-based system. In the
presence of Dox, PR/Gal4 is expressed; however, its autocatalytic
activity results in the separation of the Gal4 domains, resulting in lack of
eGFP expression. However, in the presence of PI, the PR/Gal4 fusion
remains intact, resulting in the induction of eGFP expression. The same
result is expected with an inactive mutant PR, but without the need of
inhibitor.
doi:10.1371/journal.pone.0010940.g001
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line easily infected by HIV-1 and broadly utilized in HIV-1
studies. The UAS reporter element and Gal4 or PR/Gal4 fusions
were transferred into lentiviral vectors. First, the reporter sequence
was inserted into an HIV-based self-inactivating vector, with most
of the 39 LTR U3 sequence deleted for safety reasons as well as to
ensure that the reporter activity is based only on the 5xUAS
element of the reporter and not the viral promoter. In addition,
this ensures that there will be no background reporter activity in
the absence of inhibitor. The reporter lentiviral vector is referred
to as pH-5xUAS-eGFP (Fig. 3A). As mentioned before, we
wanted to create a system that enabled inducible expression of the
PR/Gal4 fusions in order to circumvent the possible cytotoxicity
of PR when expressed in mammalian cells.
In order to obtain an inducible cell line, we utilized the
tetracycline inducible (Tet-On) system (adapted from Clontech). In
this system, rtTA binds to and activates expression from the
Tetracycline Response Element (TRE) only in the presence of Tet
or Dox. For this purpose, two retroviral/lentiviral vectors were
constructed. One of the vectors carries the rtTA element coupled
to mCherry through an Internal Ribosome Entry Site (IRES),
allowing corroboration of rtTA expression based on red
fluorescence (pBMN-i-rtTA plasmid in Figure 3A). The second
vector harbors a 7x TRE element upstream Gal4, PRm/Gal4, or
PR/Gal4: pH-TRE vectors in Figure 3A).Viral particles were
produced as described in the ‘Methods’ section using the reporter,
and rtTA plasmids, and the viral supernatant was collected and
used to transduce SupT1 cells. A stable cell line expressing these
elements was then transduced with viral particles carrying Gal4
(pH-TRE-Gal4), PRm/Gal4 (pH-TRE-PRm/Gal4) or PR/Gal4
(pH-TRE-PR/Gal4). When SupT1 cells were transduced with
lentiviral particles containing the reporter vector alone, no
detectable eGFP expression was observed and similar results were
obtained with virus encoding inducible Gal4 alone (Fig. 3B).
Importantly, when cells were co-infected with virus containing
reporter, rtTA and inducible Gal4, or inducible PRm/Gal4, eGFP
expression was undetectable. However, when these cells were
treated with 1mg/mL of Dox, eGFP expression was clearly
induced (Fig. 3B), confirming the inducibility of the system and
hence PR expression in T-cells.
Importantly, the TRE-PR/Gal4 population showed very low
eGFP expression, even after the addition of Dox. However, when
these cells were treated with 10mM IDV, a large induction of
eGFP expression was observed (Fig. 3B), thus validating the assay
and the utility of eGFP as a biosensor for the inhibitory activity of
antivirals, at least IDV, on PR in SupT1 cells.
Generation and selection of clonal stable cell lines with
the best sensitivity
Previous experiments were performed with non-clonal cell
populations. The goal of the assay, however, was to design an
assay in T-cells with a definitive and robust readout. Therefore, we
aimed to purify and amplify specific clones from the population
that displayed the lowest degree of background and the highest
level of eGFP expression in response to the appropriate treatment.
For this purpose, the initially transduced cell populations
harboring rtTA, eGFP reporter construct and either Gal4, PR/
Gal4 or PRm/Gal4 were pre-incubated with 10mM IDV. Cells
were then sorted 24 hours later based on eGFP expression in order
to enrich for those cells with an activatable reporter and an
inducible transcription factor. Seven days later, after the eGFP
from the previous activation disappeared, one more round of
sorting was performed under identical conditions, followed by a
final round of sorting at day 14. However, in this final round,
sorting was performed to isolate cells with no eGFP expression (i.e.
cells with little to no background), which resulted in a cell
population that was up to 80% positive for eGFP after activation,
with nearly zero background (Fig 3C).
Lastly, individual cells from the sorted populations (negative for
eGFP expression when untreated), were plated in a 96 well-plate
format. Single clones were expanded to obtain clonal cell lines,
which were subsequently activated using the previously described
Figure 2. Transient expression of the assay components in
HEK293T cells. (A) Vectors used for the transient expression of the
assay. The constructs include the eGFP reporter vector and the
mammalian expression vectors for Gal4, PRm/Gal4 and PR/Gal4. (B)
Top Panel: Fluorescence microscopy of cells 24 hours post transfection
with reporter alone (-), or together with either the Gal4, PRm/Gal4, or
PR/Gal4 vectors with or without PI. Bottom panel: Cells were analyzed
by flow cytometry at 24 hours post transfection. Percentage of eGFP
expressing cells is indicated for each treatment. Black and dark grey
histograms are with or without 10mM IDV. (C) Quantification of eGFP
expression, indicative of PR inhibition, based on flow cytometry data.
Results shown are average of three independent experiments.
doi:10.1371/journal.pone.0010940.g002
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highest response to appropriate conditions (data not shown).
Individual clones with maximal eGFP activation were selected for
each of the inducible elements; Gal4, PRm/Gal4 and PR/Gal4.
The selected clones exhibited almost 100% activation with nearly
undetectable background (Fig 3C). These clones were then
expanded and further analyzed in the following experiments.
Optimization and kinetics of the assay
In order to optimize the assay for maximal induction of Gal4,
PRm/Gal4 or PR/Gal4, we analyzed the effect of increasing levels
of Dox in the assay. Cells treated with 0, 50, 100, 250, 500, 750,
1,000, and 2,000 ng/mL Dox, were either treated with DMSO or
10mM IDV and analyzed 32 hours later (Fig. 4A). TRE-Gal4 cells
reached saturation with Dox at about 1,000ng/mL irrespective of
the presence of IDV. Surprisingly, TRE-PRm/Gal4 was induced
at lower levels of Dox, and reached saturation at around 250ng/
mL in both IDV-treated and untreated cells. Again, as with
Figure 3. Establishment of a clonal T-cell line stably expressing
inducible assay elements. (A) Constructs utilized to generate
infectious particles for the transduction of SupT1 cells with the various
assay elements (the rtTA, eGFP reporter, and Gal4-based vectors: Gal4,
PR/Gal and PRm/Gal4). (B) Flow cytometry analysis of selected clones.
Clones expressing the elements of the assay were analyzed with no
treatment, with 1mg/mL Dox, or with 1mg/mL Dox and 10mM IDV. (C)
Quantification of eGFP expression (left axis and larger bars) and the
relative fluorescence intensity (RFI) of each sample (right axis and green
bars within larger bars) of clones treated as indicated. The RFI was
calculated by normalizing green mean fluorescence intensity (MFI) to
the brightest MFI observed (PRm with Dox + IDV).
doi:10.1371/journal.pone.0010940.g003
Figure 4. Determination of the optimal conditions for the
screening of active PIs. Clonal SupT1 cells harboring inducible Gal4,
PRm/Gal4, or PR/Gal4 were activated in a 96 well-plate format under
various conditions. (A) Doxycycline titration. Cells were pre-incubated
with either DMSO or 10mM IDV and then either left untreated, or
activated with 50, 100, 200, 500, 1,000, or 2,000ng/mL of Dox. Cells were
analyzed by flow cytometry to determine the number of eGFP positive
cells. (B) Time course analysis of eGFP induction in response to Indinavir
with or without Dox. Cells were pre-incubated with 10mM IDV and then
either left untreated, or activated with 1mg/mL Dox. Cells were analyzed
4, 8, 12, 16, 20, 25, 50 or 75 hours after activation by flow cytometry.
doi:10.1371/journal.pone.0010940.g004
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to no detectable eGFP expression at any given Dox concentration
in the absence of 10mM IDV. However, pre-incubation of TRE-
PR/Gal4 cells with 10mM IDV showed maximal eGFP induction
at around 500ng/mL Dox. This trend was similar to that observed
in the transient expression experiment.
Next, in order to determine the optimal time point for the
analysis of eGFP expression in the assay, cells were activated with
Dox and analyzed by flow cytometry at various time points. Cells
were treated either with DMSO alone as vehicle control, or 1mg/
mL Dox and 10mM IDV (Fig. 4B). DMSO-treated cells showed
no fluorescence throughout the experiment. However, Dox-
activated cells incubated with IDV showed initial induction of
eGFP expression at about 8 hours and reached nearly 100% at
about 50 hours post-induction.
Assay response to other PIs
Finally, a preliminary screening was performed with eight other
FDA-approved PIs to ensure that the assay is not specific for IDV
and is sensitive to other inhibitors as well. For this purpose, cells
were incubated with DMSO alone, as described above (data not
shown), or with increasing concentrations of Atazanavir, Ampre-
navir, Darunavir, Nelfinavir, Lopinavir, Ritonavir, Saquinavir or
Tipranavir, as well as IDV (Fig. 5). We have chosen a broad
concentration range (from 1nM to 20mM) including the ones most
commonly used in cell culture as well as the low ranges that are
typically not active in less sensitive assays.
From our data, it is clear that Darunavir and Atazanavir had
the strongest inhibitory effects on PR activity, resulting in eGFP
expression at just 1nM, while IDV and Tipranavir, showed the
weakest inhibitory effects, nevertheless achieving full induction of
eGFP expression at about 5mM. Interestingly, all the tested PIs
resulted in increasing eGFP expression levels with increasing
inhibitor concentrations, up to 20mM, the maximal level tested.
However, Lopinavir and Nelfinavir resulted in cell death at a
concentration of about 1mM, with significant decline in the
number of eGFP positive cells, as was the case with Saquinavir at
20mM. Overall, all the inhibitors tested showed significant
inhibitory effect on PR activity and resulted in the activation of
eGFP expression in our SupT1 clone.
Discussion
In spite of the existence of various bacterial or yeast cell based
HIV PR assays, only few are mammalian cell-based; of these, none
are in a cell type actually infected by HIV-1. In order to achieve
high-throughput screening of HIV PIs in a relevant setting with a
high readout, we have produced a stable T-cell line that can be
used as a sensitive indicator of HIV-1 PR activity. We expect this
assay to greatly facilitate biological screenings, using peptide or
chemical compound based libraries, and thus result in the
discovery of novel PIs in T-cells in a straightforward and prompt
manner.
In the assay, the PR/Gal4 fusion was able to activate the
reporter vector in HEK293T cells in transient experiments only in
the presence of the inhibitors, as expected. This proved that the
assay functions as anticipated, and was thus transferred into
retroviral vectors for stable expression in T-cells. Stable cell lines
exhibited little to no detectable levels of background eGFP
expression, a critical factor for the efficient and reliable utilization
of the assay in high-throughput screenings. The Off/On inducible
expression of the PR fusion protein proved to be effective and
highly Dox dependent. Importantly, the inducible system results in
the expression of PR only at the time of the screening process, thus
preventing their possible cytotoxic effects prior to that, as
demonstrated by the viability of the clonal cell line at least for
the time period analyzed.
Additionally, the mean fluorescence intensity of eGFP in the
activated clones steadily increased, as inhibited cells continued to
accumulate higher levels of eGFP, making the cells capable of
detecting extremely low levels of PR inhibition over time, as seen
in Fig 5.
An unexpected observation was the transactivational activity of
the PR D25A mutant variant described as catalytically inactive
(PRm). Based on previous reports, the insertion of the PRm
sequence was expected to have little effect on the ability of Gal4 to
transactivate the reporter plasmid. While the percentage of
positive cells with or without IDV remained the same, surprisingly,
the relative fluorescence intensity (RFI) increased significantly with
the addition of inhibitor. Thus, the further increase in fluorescence
intensity was unexpected, as full activation was anticipated to be
independent of PI addition. This was consistent with the results
obtained in the transient experiments as well. These findings hint
at the possibility that PR D25A is not a completely inactive form of
PR or possibly may be targeted by an unknown cellular protease.
In either case, this observation corroborates the sensitivity and
usefulness of this assay, not only for the analysis of HIV PR
activity, but also for the study and characterization of other PR
variants, wild-type or mutant, and of other proteases in general,
viral as well as cellular. The potential partial activity of PR D25A
in T-cells as observed in our assay has not been previously
described and certainly warrants future research. This observation
also re-enforces the fact that the assay, developed in T-cells, may
provide a more accurate environment for antiviral drug discovery
against HIV.
Importantly, the elements of the assay, expressed in the human
T-cell lymphoblastic lymphoma cell line, SupT1, can easily be
transferred into other relevant cell types known to be vital for the
establishment of HIV infection, such as macrophages and
dendritic cells. Furthermore, the assay can be used to study the
molecular evolution of PR, by replacing the wild-type PR
sequence with PR mutants arising in patients, untreated and
Figure 5. Assay response to FDA-approved PIs. The selected
SupT1 clone expressing rtTA, the 5xUAS-eGFP reporter and an inducible
PR/Gal4 were incubated with various concentrations of Amprenavir,
Atazanavir, Darunavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, or
Tipranavir, as well as Indinavir, and then activated with 1mg/mL Dox and
analyzed 50 hours later by flow cytometry.
doi:10.1371/journal.pone.0010940.g005
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determine the appearance of drug resistance.
The assay is designed to facilitate the efficient screening for
novel inhibitory chemical compounds or peptides in a simple flow
cytometry-based platform. The lack of background noise in the
assay and clear distinction between negative and positive hits will
allow screening to be conducted with high efficiency and minimal
false positives. Additionally, the eGFP-based readout will allow
screening of millions of candidates (through rational or non-
rational based approaches) in a single experiment, with extreme
sensitivity. The inhibition by other FDA-approved PR inhibitors
proved that the applicability and sensitivity of the assay is not
limited to IDV, validating once again the ability to utilize eGFP
expression as a biosensor for PR activity in SupT1 cells. In this
respect, it is worth mentioning that Tipranavir, although
considered one of the most potent inhibitors, demonstrated lower
potency in our assay. While this fact may be of biological
significance, Tipranavir still fully activated the reporter gene at
5mM. Therefore, all FDA-approved PIs had inhibitory effects in
our assay, at concentrations well within the range of testable
concentrations for screening. Moreover, while we had chosen
10mM IDV for our proof-of-concept experiments, the assay was
clearly shown to be sensitive at lower concentrations as well.
While genotypic and phenotypic testing for HIV resistance to
antiretroviral drugs has been proven useful for individual patient
treatment management, the primary goal of the assay described
here is not to calculate IC50s of the FDA-approved drugs, but to
find new inhibitors. However, due to its high sensitivity, the assay
could be used to analyze the potency range of a specific drug, at
least as defined by the relative fluorescence intensity and
percentage of fluorescent cells. While IC50 values described in
literature vary greatly depending on the method in which they
were tested, our results show a range within those observed in
literature [30–34]. Figure 5 shows that the approximate
concentration to reach a 50% relative fluorescent intensity for
drugs such as Atazanavir, Lopinavir, Indinavir or Tipranavir is 1-
to-10nM, 10-to-50nM, 100-to-500nM and 500-to-1000nM, re-
spectively. Based on the results, a screen utilizing the assay
developed here would be optimally conducted at drug concentra-
tions up to 1mM.
Overall, we have developed an assay that can be easily adapted
to further enhance its high-throughput capacity in a flow
cytometry as well as luminescent-plate reader based format. The
assay, developed in T-cells for the first time, will greatly promote
the screening efforts for novel HIV PIs.
Materials and Methods
Cloning and Vector Construction
Gal4, PR/Gal4 and PRm/Gal4 sequences were amplified by
PCR for the production of the transient expression vectors
pcDNA-Gal4, pcDNA-PR/Gal4 and pcDNA-PRm/Gal4, respec-
tively. For this purpose, the constructs pMA236, pHP236 and
pHP236m [22] were used as templates together with the Gal4
forward primer with extending HindIII and NotI sites ACG-
CACGCaagcttgcggccgcccaccATGAAGCTACTGTCTTCTATC
and the Gal4 reverse primer with extending SalI site ATA-
GCTGCGTGCGTGCGTgtcgacttactctttttttgggtttgg. PCR prod-
ucts were digested with HindIII and SalI and ligated into
pcDNA
TM3.1/Zeocin (Invitrogen, Carlsbad CA). pFR-eGFP,
modified from pFR-Luc (Stratagene) was kindly provided by
Rainer de Martin (University of Vienna).
For the construction of the inducible vectors (pH-TRE-Gal4,
TRE-PR/Gal4 and pH-TRE-PRm/Gal4), a 7X Tet-Responsive
Element (TRE) was amplified from the pTRE-tight (Clontech)
with the forward primer with extending NruI site AGCTAGC-
TAGCTTCGCGAC ACGAGGCCCTTTCGTCTTCA and the
reverse primer with extending BsrGI site CATTTTTTT-
CACTGCCTCGAGTGTACAAGCTAGCTAGCT. The PCR
product was digested with NruI and BsrGI and cloned into the
pH-CMV-eGFP vector (Gary Nolan, Stanford University) to
replace the original CMV-eGFP cassette (creating pH-TRE). The
forward Gal4 primer with extending BamHI site ATGCATGCg-
gatccACCATGAAGCTACTGTCTTCTATC and the reverse
primer with extending NheI site GCATGCATGCTAGCT-
TACTCT TTTTTTGGGTTTGG were then used to amplify
the Gal4-based cassettes from pcDNA3.1-Gal4, pcDNA3.1-PRm/
Gal4 and pcDNA3.1-PR/Gal4, which were then inserted into
BamHI/NheI-digested pH-TRE. pBMN-i-mCherry was used for
the creation of pBMN-i-rtTA. It was constructed by amplifying
mCherry from pmCherry-C1 (Clontech) using the forward primer
with extending NcoI site ATCGATGGATCCCCACCATGGT-
GAGCAAGGGCGAGGAG and reverse primer with extending
XhoI site ATGGACGAGC TGTACAAGTAACTCGAGGAT-
CGATC, and inserting it into partially digested pBMN-i-eGFP
(Gary Nolan, Stanford University) with NcoI/SalI. pBMN-i-rtTA
was then constructed by removing rtTA from the vector Tet-OnH
(Clontech) with EcoRI/BamHI and cloning it into pBluescript-SK
(Invitrogen, Carlsbad CA), and subsequently removed with
EcoRI/XhoI and ligated into pBMN-i-mCherry.pH-5xUAS-
eGFP was constructed by digesting pFR-eGFP with MfeI/BsrGI
and ligating the resulting 5xUAS-eGFP insert into pH-CMV-
eGFP digested with MfeI/BsrGI to replace the CMV-eGFP
cassette. Transfections
For the transfection of HEK293T cells, 15ml of 2mg/mL
Polyethylenimine linear 25kD (Polysciences, Inc.) and 3mg of each
DNA was used. This mixture was added to cells grown in DMEM
media (supplemented with 10% Fetal Calf Serum (FCS), Penicillin –
Streptomycin (Pen-Strep), L-Glutamine) in a 10cm plate at ,60–
75% confluence. Cells were then analyzed by fluorescence
microscopy and/or flow cytometry 24 hours post transfection.
Production of Viral Particles for Retroviral Transduction
For the production of MLV based virus, the Phoenix GP cell-
line (Nolan Lab, Stanford University, CA) at 50–60% confluence
was transfected with 3mg of the packaging vector (pBMN-i-rtTA)
and 3mg of a vector expressing the Envelope glycoprotein of the
Vesicular Stomatitis Virus (pCI-VSVg). Media (DMEM with 10%
FCS, Pen-Strep, L-Glutamine) was replaced 24 hours post-
transfection and viral supernatant was collected 48 hours after
transfection, filtered with 0.45 micron PTFE filters (Pall Corpo-
ration) and frozen at 280uC in 1mL aliquots. For the production
of HIV based virus particles, HEK293T cells were transfected
with 3mg packaging vector (pH vectors), 2mg pCI-VSVg, 1mgo f
Viral Protein R-expressing vector (pRSV-Vpr, shown to enhance
viral titers) [35], and 3mg of pCMVD8.2, (kindly provided by
Didier Trono, EPFL, Switzerland) [36]. Media (DMEM with 10%
FCS, Pen-Strep, L-Glutamine) was replaced 24 hours post-
transfection and viral supernatant was collected 48 hours post
transfection.
Transductions
SupT1 cells, grown in RPMI supplemented with 10% FCS,
Pen-Srep, L-Glutamine, was treated with 5mg/mL Polybrene
(Hexadimethrene Bromide, Sigma) and infected with viral stocks
by centrifugation in a hanging bucket rotors centrifuge (Becton
Dickinson) at 1500RPM, for 120 minutes at 32uC. Cells were then
analyzed for expression at least 72 hours post-infection.
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Cells were checked for fluorescence on a Zeiss Observer D1
microscope with a 50X lens connected to an AxioCam MRm
camera, and analyzed on Axio-Vision software.
Flow Cytometry and Sorting
Flow Cyometry was performed on a BD FACSAria with
405nm, 488nm and 633nm lasers. Data was collected on
FACSDiva 6.1.1 software and then exported to FlowJo for
analysis.
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